Investment banking advisory firm Lincoln International (LCLN.US) applies for a US stock IPO with plans to raise up to $100 million.
Lincoln International (LCLN.US), an investment bank advisory company focused on private equity markets, submitted documents to the U.S. Securities and Exchange Commission last Friday, planning to raise up to $100 million through an initial public offering (IPO).
Focused on the private equity market, investment bank advisory company Lincoln International (LCLN.US) submitted a filing to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $100 million through an initial public offering (IPO).
Lincoln International is a global independent investment bank advisory firm that specializes in the private equity market, providing advisory services to private equity and private credit investors, private business owners, and other senior executives. The company's business covers two main areas: investment banking advisory services and valuation and opinion consulting. Lincoln International has over 30 offices in 14 countries across the Americas, Europe, the Middle East, and Asia, serving clients and conducting business operations.
Headquartered in Chicago, Illinois, the company was founded in 1996 and achieved revenue of $784 million for the 12 months ending on December 31, 2025. The company plans to list on the New York Stock Exchange (NYSE) under the ticker symbol LCLN. Lincoln International had previously submitted a confidential IPO application on May 4, 2022. Goldman Sachs Group, Inc., Morgan Stanley, BMO Capital Markets, Citizens JMP, and Evercore ISI are serving as joint bookrunners for the offering. The company has not yet disclosed pricing terms.
Related Articles

J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.






